NovaBridge Biosciences
CIK 0001778016 · NBP Nasdaq
About NovaBridge Biosciences
NovaBridge Biosciences is a non-accelerated filer incorporated in Cayman Islands, classified under SIC 2834 (Pharmaceutical Preparations). It files with the SEC under Central Index Key 0001778016, and its shares are listed as NBP on Nasdaq. Its most recent filing on EDGAR is a SCHEDULE 13D/A, filed November 5, 2026. 47 institutional investment managers reported holding its shares on Form 13F for Q3 2026, against 49 in Q2 2026. Its officers, directors and 10% owners have filed 16 Form 4 reports since 2026. 3 investors report a stake of 5% or more on Schedule 13D or 13G.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| HHLR ADVISORS LTD | $8.2M |
| MORGAN STANLEY | $4.7M |
| AIHC Capital Management Ltd | $3.9M |
| CITADEL ADVISORS LLC | $1.9M |
| Candriam S C A | $1.6M |
5%+ holders · 13D/G
3 filers| Filer | % of class | Filed |
|---|---|---|
| HHLR ADVISORS LTD 13D | 4.9% | 2026-11-06 |
| CBC Investment I-Mab Limited 13D | 11.5% | 2026-02-03 |
| Everest Medicines Limited 13D | 16.1% | 2025-08-05 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.
Insider trades · Form 4
Latest filings
- Ian Ying Woo 2026-10-19 Exercise
- Phillip Andrew Dennis 2026-09-21 Sell
- Sean Wuxiong Cao 2026-09-11 Sell
- Sean Wuxiong Cao 2026-09-08 Exercise
- Cong Claire Xu 2026-09-01 Sell
Securities
| CUSIP | Security | Type |
|---|---|---|
| 44975P103 | NBP NOVABRIDGE BIOSCIENCES | Adr |